LU 302872

Drug Profile

LU 302872

Alternative Names: BSF-302872; LU-302872

Latest Information Update: 12 Feb 2013

Price : $50

At a glance

  • Originator Abbott GmbH & Co. KG
  • Class Propionic acids; Pyrimidines; Small molecules
  • Mechanism of Action Endothelin A receptor antagonists; Endothelin B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Benign prostatic hyperplasia

Most Recent Events

  • 31 Dec 2012 Discontinued - Preclinical for Benign prostatic hyperplasia in Germany (PO) before 2012
  • 09 Dec 2003 No development reported - Preclinical for Benign prostatic hyperplasia in Germany (PO)
  • 13 Mar 2001 BASF's pharmaceutical business has been acquired by Abbott Laboratories
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top